3.81 USD
↘ 0.27 (6.62%)AT CLOSE (11:59 AM EDT)
Prelude Therapeutics Incorporated (PRLD) trades at $3.81 per share. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, PRLD is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jun 5, 2026.